Market-Moving News for July 22nd
$HEPA
$MIRA
$RR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/11/2025 | $3.50 | Buy | H.C. Wainwright | |
| 3/18/2025 | $3.00 | Buy | Lake Street | |
| 2/28/2022 | $3.50 | Overweight | Cantor Fitzgerald |
D - RICHTECH ROBOTICS INC. (0001963685) (Filer)
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
SCHEDULE 13G - RICHTECH ROBOTICS INC. (0001963685) (Subject)
LAS VEGAS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR), ("Richtech Robotics" or the "Company"), a Nevada-based provider of AI-driven service robots, announced today the closing of its previously announced private placement for the purchase and sale of 8,500,000 shares of the Company's Class B common stock priced at the market under Nasdaq rules. Rodman & Renshaw LLC acted as the exclusive placement agent for the offering. The gross proceeds from the offering were approximately $38.7 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capita
LAS VEGAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR), ("Richtech Robotics" or the "Company"), a Nevada-based provider of AI-driven service robots, announced today that it has entered into a definitive agreement with a fundamentally driven institutional investor for the purchase and sale of 8,500,000 shares of the Company's Class B common stock in a private placement priced at the market under Nasdaq rules. The private placement is expected to close on or about January 29, 2026, subject to the satisfaction of customary closing conditions. Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are ex
Joint engineering effort with Microsoft AI Co-Innovation Labs enhances Richtech's ADAM robot and extends intelligent automation across physical environments LAS VEGAS, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a U.S.-based provider of AI-driven robots operating in commercial and industrial environments, today announced a hands-on collaboration with Microsoft through the Microsoft AI Co-Innovation Labs to jointly develop and deploy agentic artificial intelligence capabilities in real-world robotic systems. Through close collaboration between Richtech Robotics' engineering team and Microsoft's AI Co-Innovation Labs, the companies worked tog
4 - RICHTECH ROBOTICS INC. (0001963685) (Issuer)
4 - RICHTECH ROBOTICS INC. (0001963685) (Issuer)
4 - RICHTECH ROBOTICS INC. (0001963685) (Issuer)
H.C. Wainwright initiated coverage of Richtech Robotics with a rating of Buy and set a new price target of $3.50
Lake Street initiated coverage of Richtech Robotics with a rating of Buy and set a new price target of $3.00
Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50
4 - RICHTECH ROBOTICS INC. (0001963685) (Issuer)
4 - RICHTECH ROBOTICS INC. (0001963685) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
Columbia University announced as first institution to join the program LAS VEGAS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada-based provider of AI-driven service robots, proudly announces the launch of the Richtech Accelerator Program. This initiative aims to bolster AI and robotics research at U.S. universities by integrating localized AI models with robotics hardware, marking a significant step forward in the advancement of localized AI systems for robots. The goal of this program is to provide AI and robotics research institutions with more technologically advanced development frameworks, granting them access to Richtech Robotic
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
Richtech Robotics' AI service robot ADAM worked alongside Delaware North at Texas Rangers' Globe Life Field LAS VEGAS, July 23, 2024 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada company and a provider of AI-driven service robots, today announces the official installation of their robotic solution ADAM at the Texas Rangers' Major League Baseball stadium, Globe Life Field. With unique AI capabilities and advanced human-like motions, ADAM will serve as the first humanoid bartender robot in any major league sports arena or large-scale entertainment venue. The launch of ADAM at Globe Life Field, in collaboration with global hospitality and entertainme
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - RICHTECH ROBOTICS INC. (0001963685) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl
